Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China
Executive Summary
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
You may also be interested in...
Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy
Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.